Erratum: Benefits of β blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis (BMJ (2013) 346 (f55) doi:10.1136/bmj.f55);Benefits of blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis

BMJ (Online)

Volumn 346, Issue 7893, 2013, Pages

  Chatterjee, Saurav ^a   Biondi Zoccai, Giuseppe ^b   Abbate, Antonio ^b   D'Ascenzo, Fabrizio ^d   Castagno, Davide ^d   Van Tassell, Benjamin ^c   Mukherjee, Debabrata ^e   Lichstein, Edgar ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; SHORT ACTING DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; BAYES THEOREM; COMPARATIVE STUDY; HEART STROKE VOLUME; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; BAYES THEOREM; HEART FAILURE; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84873350548     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f596     Document Type: Erratum

References (53)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive Summary: heart disease and stroke statistics -2012 update: a report from the American Heart Association. Circulation 2012;125:188-97.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al, for the American College of Cardiology Foundation and the American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
3. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al, for the Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail Jun 2010;16:e1-194.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
5. Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011;109:1176-94.
6. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91. (Pubitemid 28436168)
7. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5. (Pubitemid 27182346)
8. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34. (Pubitemid 27357123)
9. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-94.
10. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al, for the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. (Pubitemid 36835815)
11. Moher D, Liberati A, Tetzlaff J, Altman DG, for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
12. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005;34:224-5. (Pubitemid 40347400)
13. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
14. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
15. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42. (Pubitemid 24114241)
16. Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, et al, for the CARMEN Investigators and Co-ordinators. Tolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail 2004;6:467-75. (Pubitemid 38746591)
17. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-9. (Pubitemid 127674849)
18. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al, for the Carvedilol Hibernating Reversible Ischaemia Trial: Marker of Success Investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21. (Pubitemid 36840896)
19. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
21. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al, for the CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-35. (Pubitemid 41504492)
22. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6. (Pubitemid 26411744)
23. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. (Pubitemid 32479962)
24. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7:631-9. (Pubitemid 40732997)
25. Hjalmarson A, Goldstein S, Fagerberg B, Goldstein S, Fagerberg B, Hjalmarson A, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302. (Pubitemid 30129796)
26. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al, for the MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8. (Pubitemid 34833165)
27. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16. (Pubitemid 26411745)
28. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55. (Pubitemid 26152713)
29. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation 1996;94:2793-9. (Pubitemid 26411743)
30. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-84.
31. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al, for the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. (Pubitemid 40222359)
32. Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail 2000;2:407-12. (Pubitemid 32003339)
33. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6. (Pubitemid 24000287)
34. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al, for the Cochrane Bias Methods Group and the Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
35. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail 2009;15:5-8.
36. Waagstein F, Strömblad O, Andersson B, Böhm M, Darius M, Delius W, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail 2003;5:679-91. (Pubitemid 38043974)
37. Brodsky MA, Allen BJ, Bessen M, Luckett CR, Siddiqi R, Henry WL. Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart J 1988;115:799-808. (Pubitemid 18093146)
38. Jafri SM. The effects of beta blockers on morbidity and mortality in heart failure. Heart Fail Rev 2004;9:115-21. (Pubitemid 39485472)
39. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al, for the OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-9. (Pubitemid 351927267)
40. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008;168:2415-21.
41. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. Am J Cardiol 2007;100:690-6. (Pubitemid 47225169)
42. Fung JW, Chan SK, Yeung LY, Sanderson JE. Is beta-blockade useful in heart failure patients with atrial fibrillation An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002;4:489-94.
43. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC, for the MERIT-HF Study Group. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300-9. (Pubitemid 38998506)
44. Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007;49:963-71. (Pubitemid 46335773)
45. Intengan HD, Schiffrin EL. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 2000;35:763-8. (Pubitemid 30253618)
46. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 2007;104:16657-62. (Pubitemid 350211072)
47. Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, et al. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007;49:1722-32. (Pubitemid 46589924)
48. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, et al, for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36. (Pubitemid 39473160)
49. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 2011;17:664-9.
50. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
51. Brophy JM, Joseph L, Rouleau JL. β-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134:550-60. (Pubitemid 32245316)
52. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, et al. Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol 2011;58:915-22.
53. Lazarus DL, Jackevicius CA, Behlouli H, Johansen H, Pilote L. Population-based analysis of class effect of β blockers in heart failure. Am J Cardiol 2011;107:1196-202.